FDA Inspection 1307164 — argenx BV
The FDA completed an inspection of argenx BV on March 6, 2026 in Boston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 6, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Boston, MA (United States)
Additional Details
Sponsor, Contract Research Organization